Company intelligence

ACRS

Aclaris Therapeutics, Inc. · NASDAQ · Healthcare

Price$6.02-0.50% · −$0.03

Market cap840.78MEquity value

P / E-10.4Trailing ratio

Volume1.49MLatest session

Market data

ACRS price chart

TradingView

Related signals

1 min delayed

Browse public ACRS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ACRSDec 23, 2024-0.85% since signal

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

ACRS upgraded to Buy with $20 price target, stock gains 8%. Exclusive deal for BSI-045B may address unmet medical needs. Potential market for BSI-045B could yield $9.8 billion in peak sales. Approval probabilities for BSI-045B at 30% for asthma, 20% for dermatitis.

View signal analysis

ACRSNov 19, 2024-16.88% since signal

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Aclaris licensed BSI-045B for global rights, excluding Greater China. BSI-045B shows promise for atopic dermatitis with positive Phase 2a results. Leerink upgraded ACRS, boosting price target from $2 to $7. Biosion receives $40 million upfront and potential $900 million in milestones. ACRS shares increased 55.60% following recent developments.

View signal analysis

ACRSJul 25, 2024+1.08% since signal

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

ACRS ranks #4 in Medical sector with strong performance. Zacks Rank #2 indicates a 'Buy' rating for ACRS. Earnings estimates for ACRS increased by 21.2% recently. ACRS has returned 31.4% this year, outperforming sector's 7.3%. ACRS is better positioned than its industry peers.

View signal analysis

Research